Latest Breaking News On - Gastroenteropancreatic neuroendocrine tumors - Page 1 : comparemela.com

Cipla gets USFDA nod for its generic formulation to treat pancreatic cancer

Cipla gets USFDA nod for its generic formulation to treat pancreatic cancer
financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.

United statesCipla lanreotideDrug administrationCipla limited onCipla limitedAbbreviated new drug applicationLanreotide injectionUnited states foodSomatuline depotGastroenteropancreatic neuroendocrine tumorsCovaxin side effects

Cipla secures USFDA approval for pancreatic disease injection, shares surge

Cipla secures USFDA approval for pancreatic disease injection, shares surge
oklahomacitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from oklahomacitysun.com Daily Mail and Mail on Sunday newspapers.

United statesDrug administrationUnited states foodLanreotide injectionSomatuline depotGastroenteropancreatic neuroendocrine tumorsLanreotide acetate

Cipla receives final approval for the generic version of Somatuline® Depot (Lanreotide) Injection 120 mg/ 0 5 mL, 90 mg/0 3 mL, 60 mg/0 2 mL

/PRNewswire/ Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") and its wholly owned subsidiary Cipla USA Inc., (hereafter.

United statesSouth africaCipla lanreotideCipla united states incDrug administrationPrnewswire cipla limitedAbbreviated new drug applicationLanreotide injectionUnited states foodGastroenteropancreatic neuroendocrine tumorsNorth america

177Lu-Dotatate Prolongs PFS vs High-Dose Octreotide in GEP-NETs

Lutetium Lu 177 dotatate plus octreotide significantly improved PFS vs high-dose octreotide in patients with gastroenteropancreatic neuroendocrine tumors.

Advanced accelerator177lu dotatateGep netsGastroenteropancreatic neuroendocrine tumorsNeuroendocrine tumorsLutetium lu 177 dotatateSomatostatin analogPhase 3 netter 2 trial2024 gastrointestinal cancers symposiumAsco giSimron singhSunnybrook health sciences centre

FDA Accepts Filing of Abbreviated NDA for Generic Lutathera in GEP-NETs

The FDA has accepted the filing of an abbreviated new drug application (ANDA) for Lutetium Lu 177 Dotatate, a generic version of lutetium Lu 177 dotatate indicated for the treatment of patients with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors in adults.

United statesJoe mccannMary anne heinoUniversity health networkAnne heinoGastrointestinal cancerGi cancerLutetium lu 177 dotatateGep netsGastroenteropancreatic neuroendocrine tumors